|
|
| | TAUROURSODEOXYCHOLIC ACID SODIUM SALT Basic information |
| | TAUROURSODEOXYCHOLIC ACID SODIUM SALT Chemical Properties |
| Melting point | 173-175°C | | alpha | +40～+50°(D/20℃) | | storage temp. | Inert atmosphere,Store in freezer, under -20°C | | solubility | DMSO (Slightly, Heated), Ethanol (Slightly, Sonicated), Methanol (Slightly) | | form | Solid | | color | Off-White to Pale Beige | | Water Solubility | water: 100mg/mL | | InChIKey | WSSCRQYICWZEFG-SXXADWEANA-N | | SMILES | C[C@]12CC[C@]3([H])[C@]4(CC[C@@H](O)C[C@@]4([H])C[C@H](O)[C@@]3([H])[C@]1([H])CC[C@]2([H])[C@H](C)CCC(=O)NCCS(O)(=O)=O)C.[NaH] |&1:1,4,6,9,12,15,17,19,23,25,r| |
| WGK Germany | 2 | | RTECS | KI7372500 | | HS Code | 2924297099 |
| | TAUROURSODEOXYCHOLIC ACID SODIUM SALT Usage And Synthesis |
| Chemical Properties | Off-White Solid | | Uses | Tauroursodeoxycholic Acid Sodium Salt is a bile related salt for isolation of lipids and membrane-bound proteins. It is a sodium salt form of Tauroursodeoxycholic Acid which can be used in biological study of inhibition of alpha-naphthyl isothiocyanate-induced liver injury and bile acid cycle disruption by glycyrrhizin and glycyrrhetinic acid. | | Uses | Sodium tauroursodeoxycholate has been used in a study to assess whether ER stress is involved in palmitic acid upregulation (PA). It has also been used in a study to investigate its effect on Estradiol-17β-D-glucuronide (E-17G) induced cholestasis in female rats. | | Uses | Tauroursodeoxycholate inhibits human cholangiocarcinoma growth via Ca2+-, PKC-, and MAPK-dependent pathways. | | General Description | Sodium tauroursodeoxycholate is a bile salt which is naturally present in the small bowel. | | in vivo | The effects of Tauroursodeoxycholate (TUDCA) on proliferation and apoptosis of VSMCs in vivo are examined using immunohistochemistry. Tauroursodeoxycholate (10, 50, and 100 mg/kg) increases the caspase 3 activity of injured tissues in a dose-dependent manner, indicating that Tauroursodeoxycholate induces apoptosis of VSMCs in the neointima. Using the injured tissues, further examination and comparison of the phosphorylation level of ERK and MMP-9 expression is performed at 1 week after injury, compared with normal controls. Balloon injury increased both the phosphorylation of ERK and expression of MMP-9 in the tissues. Tauroursodeoxycholate (10, 50, and 100 mg/kg) inhibits phosphorylation of ERK and MMP-9 expression in a dose-dependent manner[1]. Tauroursodeoxycholate (TUDCA) is a hydrophilic bile acid. Tauroursodeoxycholate as a cytoprotective agent improves liver function and can prevent hepatocellular carcinoma by reducing ER stress and apoptosis. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3, caspase-12, C/EBP homologous protein, c-Jun N-terminal kinase (JNK), activating transcription factor 4 (ATF4), X-box binding protein (XBP), and eukaryotic initiation factor 2α (eIF2α) in Ang II induced ApoE-/- mice (p<0.05). Tauroursodeoxycholate reduces Angiotensin (Ang) II induced abdominal aortic aneurysm (AAA)? formation in ApoE-/- mice. Tauroursodeoxycholate is used at a dose of 0.5 g/kg/day in treating Ang II induced ApoE-/- mice (ER stress inhibitor group). Systolic blood pressure (141.3±5.6 mmHg vs 145.9±8.9 mmHg; p>0.05) and total cholesterol levels (663.6±88.7 mg/dL vs 655.7±65.4 mg/dL; p>0 .05) do not differ between the AAA model group and Tauroursodeoxycholate group. In addition, maximum aortic diameter is significantly smaller in those in Tauroursodeoxycholate group compared with those in the AAA model group (0.95±0.03 mm vs 1.79±0.04 mm; p<0.05). AAA lesion areas are also smaller in those in Tauroursodeoxycholate group than in those in the AAA model group (0.37±0.03 mm2 vs 1.51±0.06 mm2; p<0.05)[2]. | | IC 50 | ERK; Caspase-3; Caspase-12; Human Endogenous Metabolite |
| | TAUROURSODEOXYCHOLIC ACID SODIUM SALT Preparation Products And Raw materials |
|